The table below shows Esperion Therapeutics, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q3 2025
Q2 2025
Q1 2025
Q3 2024
Q2 2024
Revenue
$80.10M
$87.31M
$82.39M
$65.00M
$51.63M
$73.83M
Cost of revenue
-
-
-
-
-
-
Gross profit
-
-
-
-
-
-
R&D
-
-
-
-
-
-
SG&A
ESPR annual revenue (10-K history)
Esperion Therapeutics, Inc. reported annual revenue of $403.13M for fiscal year 2025. That is up 21.3% from $332.31M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.